e-learning
resources
Vienna 2009
Tuesday, 15.09.2009
Aetiology and treatment of community-acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A clinical and aetiological evaluation of community acquired pneumonia-are we following guidelines in prescribing antibiotics?
N. A. Naji, H. Muhammed, B. McCullagh, R. Obaze, P. O‘Brien (Naas, Dublin, Ireland)
Source:
Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia
Session:
Aetiology and treatment of community-acquired pneumonia
Session type:
E-Communication Session
Number:
3201
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. A. Naji, H. Muhammed, B. McCullagh, R. Obaze, P. O‘Brien (Naas, Dublin, Ireland). A clinical and aetiological evaluation of community acquired pneumonia-are we following guidelines in prescribing antibiotics?. Eur Respir J 2009; 34: Suppl. 53, 3201
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
The impact of national recommendations on antibiotic treatment of community acquired pneumonia. Do pediatricians follow the national guidelines?
Source: International Congress 2017 – Pulmonary infection and inflammation
Year: 2017
Antibiotic therapy of community-acquired pneumonia in the hospital setting: national guidelines and real clinical practice.
Source: International Congress 2017 – COPD management
Year: 2017
Clinical effectiveness of recommended antibiotics in COVID19 pneumonias; assessing national referral centre guidance
Source: Virtual Congress 2021 – COVID - 19 treatments
Year: 2021
Clinical management of COPD: recommended practice including the place of antibiotics
Source: Annual Congress 2008 - PG1 - EU GRACE network full-day course: Antibiotics or not: from acute bronchitis to acute exacerbation of chronic bronchitis
Year: 2008
Clinical case discussion: How clinical trials inform antibiotic stewardship
Source: ERS webinar 2022: Clinical case discussion: How clinical trials inform antibiotic stewardship
Year: 2022
Prescriptions for treatment in patients with PCD: does clinical routine match recommendations?
Source: Virtual Congress 2020 – Worldwide respiratory disease across the full spectrum
Year: 2020
Can CAP guideline adherence improve patient outcome in internal medicine departments?
Source: Eur Respir J 2008; 32: 902-910
Year: 2008
Clinical management: recommended practice including the place of antibiotics
Source: Annual Congress 2007 - PG24 - GRACE full-day course. From cough to asthma: the role of infection
Year: 2007
Treatment of childhood asthma in Malaysia: adherence of general practice preferences to clinical practice guidelines
Source: Eur Respir J 2002; 20: Suppl. 38, 332s
Year: 2002
Use and misuse of clinical and evidence-based guidelines in clinical practice
Source: Annual Congress 2009 - Physiotherapy for the respiratory patient: evidence-based guidelines
Year: 2009
Local antibiotic guidelines for management of adult community acquired pneumonia in UK hospitals
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Management of community acquired pneumonia in UK hospitals: a survey of the availability of local guidelines and severity assessment tools
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Community acquired pneumonia in Greece: clinical, laboratory data – adherence to the international guidelines
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Current approaches to formulate evidence-based recommendations: a case study of WHO drug-resistant tuberculosis treatment guidance
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Community acquired pneumonia guidelines: not only treatment indications
Source: Annual Congress 2004 - PG22 - New perspectives in pneumonia treatment and prophylaxis
Year: 2004
Are severity scores for community acquired pneumonia being used in secondary care and its impact on appropriateness of antibiotic therapy - a retrospective study
Source: Eur Respir J 2004; 24: Suppl. 48, 187s
Year: 2004
The new WHO air quality guidelines: policy and clinical implications for children with respiratory diseases
Source: Virtual Congress 2021 – The environment and climate change effects on lung health across the lifecourse
Year: 2021
From international guidelines to local guidelines for nosocomial pneumonia: what is missing?
Source: International Congress 2019 – Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution
Year: 2019
New antibiotics into clinical practice
Source: Annual Congress 2004 - PG18 - Childhood pneumonia after the turn of the new millennium
Year: 2004
Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities
Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept